Calidi Biotherapeutics, Inc. (CLDI) AMEX
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 0.17 |
| Open | 0.17 |
| Day High | 0.17 |
| Day Low | 0.16 |
| 52-Week High | 19.2 |
| 52-Week Low | 0.16 |
| Volume | 1.8M |
| Average Volume | 4.71M |
| Market Cap | 1.21M |
| PE | -0.04 |
| EPS | -4.17 |
| Moving Average 50 Days | 0.21 |
| Moving Average 200 Days | 0.95 |
| Change | -0 |
Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters’ Over-Allotment Option
GlobeNewswire Inc.
Mar 10, 2026 12:50 AM GMT
$12 Million of Tranche Warrants Potential Financing Within One Year From ClosingSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the dev
Calidi Biotherapeutics Announces Pricing of $5.2 Million Underwritten Public Offering
GlobeNewswire Inc.
Mar 06, 2026 1:30 PM GMT
Short Term Tranche Warrants Potentially Raise $10.4 Million within 12 months of ClosingSAN DIEGO, March 06, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
GlobeNewswire Inc.
Feb 20, 2026 1:00 PM GMT
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approac